SequelSEC

LIPELLA PHARMACEUTICALS INC. LIPO

Pharmaceutical Preparations · CIK 0001347242 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$536.36K
Fiscal year ended 2024-12-31
Operating income
-$5.08M
Fiscal year ended 2024-12-31
Free cash flow
Unavailable
Fiscal year ended 2024-12-31

LIPELLA PHARMACEUTICALS INC. (LIPO) reported revenue of $536.36K and net income of -$5.02M for the fiscal year ended 2024-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from LIPELLA PHARMACEUTICALS INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

LIPELLA PHARMACEUTICALS INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-31
Revenue$536.36K$449.62K$184.16K$259.35K
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$5.08M-$4.75M-$2.59M-$1.92M
Net income-$5.02M-$4.62M-$2.60M-$1.87M
Research & development$3.61M$3.04M$2.55M$1.46M
Weighted-average diluted sharesshares 1.05MUnavailableshares 4.06Mshares 3.41M
Pretax income-$5.02M-$4.62M-$2.60M-$1.87M
Income tax expenseUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-4.79$-6.16$-0.64$-0.55
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$2.00M$2.16M$226.19K$718.38K
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

LIPELLA PHARMACEUTICALS INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-31
Cash & equivalents$2.18M$3.29M$5.12M$1.41M
Total assets$2.67M$3.58M$5.95M$2.01M
Current assets$2.62M$3.43M$5.80M$1.81M
Total liabilities$754.42K$432.73K$1.27M$589.34K
Current liabilities$754.42K$385.36K$1.18M$340.62K
Total equity incl. NCI$1.92M$3.14M$4.68M$1.42M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivable$84.71K$32.29K$113.66KUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$388.19K$138.02K$384.36K$46.90K

Cash flow

LIPELLA PHARMACEUTICALS INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-31
Operating cash flow-$3.95M-$3.15M-$1.83M-$989.27K
Capital expendituresUnavailable$14.43KUnavailableUnavailable
Investing cash flowUnavailable-$14.43K$300.55K-$300.55K
Financing cash flow$2.84M$1.34M$5.24M$2.10M
Net change in cashUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$2.89K$1.68KUnavailableUnavailable

Derived

LIPELLA PHARMACEUTICALS INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-31
Free cash flowUnavailable-$3.16MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating margin-947.2%-1055.6%-1406.3%-738.7%
FCF marginUnavailable-703.8%UnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio3.47x8.90x4.92x5.31x
Revenue YoY growth19.3%144.2%-29.0%Unavailable
Net margin-935.2%-1027.3%-1410.6%-719.3%
R&D / revenue673.7%675.9%1383.4%561.7%
CapEx / revenueUnavailable3.2%UnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LIPO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing
10-K · Filed 2025-03-28View SEC filing
10-Q · Filed 2024-11-14View SEC filing
10-Q · Filed 2024-08-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.